

Please enter the following amendments and remarks.

Listing of the claims:

What is claimed is:

1. - 48. (Canceled)

49. (Currently amended) A method for detecting bladder cancer in a human test subject, said method comprising:

a) Quantifying ~~in RNA of a blood sample from said test subject, a level of RNA encoded by the gene a~~ Homo sapiens tumor necrosis factor receptor superfamily, member 7 (TNFRSF7) gene in said a blood sample of said test subject; and

b) Comparing said quantified level of RNA in said sample of said test subject with a quantified level of control RNA encoded by said gene in ~~RNA of blood samples from of~~ control subjects which are classified as healthy control subjects; and

c) comparing said level of RNA in said sample of said test subject a quantified level of control RNA encoded by said gene in blood samples of control subjects which are classified as having bladder cancer;

wherein said comparison of a statistically significant determination resulting from steps (b) and (c) that expression of said quantified level of step (a) with gene in said sample of said test subject is different relative to said quantified level of said samples of said control subjects classified as healthy control subjects, and is similar relative to said samples of said control subjects classified as having bladder cancer is indicative of bladder cancer in said human test subject.

50. (Currently amended) The method of claim 49, wherein said blood sample of step (a)said test subject and said blood samples from of said control subjects in step (b) have not been fractionated into cell types.

51. (Cancelled)

52. (Currently amended) The method of ~~any of claims 49, 50 or 51~~claims 49, 50 or 51, wherein said quantifying of said level of ~~said~~ RNA encoded by said gene in said sample of said test subject in step (a) is effected ~~by quantifying said RNA relative to a housekeeping gene.~~

53. (Currently amended) The method of ~~any of claims 49, 50 or 51~~claims 49, 50 or 51, wherein said quantifying of said level of ~~said~~ RNA encoded by said gene in said sample of said test subject in step (a) is effected by quantification of cDNA corresponding complementary to said RNA encoded by said gene.

54. (Cancelled)

55. (Canceled )

56. (Currently Amended) The method of ~~any of claims 49 or claim 60, 50 or 51~~claims 49 or claim 60, 50 or 51, wherein said quantifying of said level of ~~said~~ RNA encoded by said gene ~~in step (a)~~ is ~~determined effected~~ using quantitative ~~real time~~ RT-PCR.

57. (Currently amended) The method of ~~any of claims 49 or claim 60, 50 or 51~~claims 49 or claim 60, 50 or 51, wherein said quantifying of said level of ~~said~~ RNA encoded by said gene ~~in step (a)~~ is ~~determined effected~~ using an array.

58. (New) A method for detecting expression of a Homo sapiens tumor necrosis factor receptor superfamily, member 7 (TNFRSF7) gene in a human test subject, said method comprising detecting RNA encoded by said gene in a blood sample of said test subject, using an oligonucleotide of predetermined sequence which is specific only for RNA encoded by said gene in said sample, and/or for cDNA complementary to RNA encoded by said gene in said sample.

59. (New) The method of claim 58, wherein said detecting of said RNA comprises producing an amplification product from RNA encoded by said gene in said blood sample of said test

subject, using primers specific only for RNA encoded by said gene and/or for cDNA complementary to RNA encoded by said gene.

60. (New) The method of claim 58 or claim 59, further comprising quantifying a level of RNA encoded by said gene in said sample.

61. (New) The method of claim 60, further comprising comparing said level of RNA to a quantified level of control RNA encoded by said gene in blood samples of control subjects.

62. (New) The method of claim 61, wherein said control subjects are selected from the group consisting of: subjects classified as healthy subjects and subjects classified as having bladder cancer.

63. (New) The method of claim 62, wherein said control subjects are classified as healthy subjects.

64. (New) The method of claim 63, further comprising classifying said test subject as being a candidate for having bladder cancer if said level of RNA encoded by said gene in said blood sample of said human test subject is lower than that of said control subjects classified as healthy subjects.

65. (New) The method of claim 63, further comprising identifying said test subject as being a candidate for having bladder cancer if said level of RNA encoded by said gene in said blood sample of said human test subject is at least 3 times lower than that of said control subjects classified as healthy subjects.

66. (New) The method of claim 63, further comprising identifying said test subject as being a candidate for having bladder cancer if said level of RNA encoded by said gene in said blood sample of said human test subject is 3.2 times lower than that of said control subjects classified as healthy subjects.

67. (New) The method of claim 65, wherein said gene is differentially expressed in said blood sample of said human test subject relative to said samples of said control subjects classified as healthy subjects with a p value less than 0.05.

68. (New) The method of claim 66, wherein said gene is differentially expressed in said blood sample of said human test subject relative to said samples of said control subjects classified as healthy subjects with a p value equal to 0.04.

69. (New) A method of screening a human test subject for being a candidate for having bladder cancer, said method comprising:

(a) detecting RNA encoded by a Homo sapiens tumor necrosis factor receptor superfamily, member 7 (TNFRSF7) gene in a blood sample of said test subject, using an oligonucleotide of predetermined sequence which is specific only for RNA encoded by said gene in said sample, and/or for cDNA complementary to RNA encoded by said gene in said sample; and

(b) quantifying a level of RNA encoded by said gene in said sample of said test subject; and

(c) comparing said level of RNA in said sample of said test subject to a quantified level of control RNA encoded by said gene in blood samples of control subjects classified as healthy subjects;

wherein said test subject is a candidate for having bladder cancer if said level of RNA encoded by said gene in said blood sample of said test subject is at least 3.2 times lower than said level of RNA encoded by said gene in said samples of said control subjects classified as healthy subjects with a p value less than 0.05.

70. (New) A method of screening a human test subject for being a candidate for having bladder cancer, said method comprising:

(a) detecting RNA encoded by a Homo sapiens tumor necrosis factor receptor superfamily, member 7 (TNFRSF7) gene in a blood sample of said test subject, using an oligonucleotide of predetermined sequence which is specific only for RNA encoded by

said gene in said sample, and/or for cDNA complementary to RNA encoded by said gene in said sample; and

(b) quantifying a level of RNA encoded by said gene in said sample; and

(c) comparing said level of RNA in said sample of said test subject to a quantified level of control RNA encoded by said gene in blood samples of control subjects classified as healthy subjects;

wherein said test subject is a candidate for having bladder cancer if said level of RNA encoded by said gene in said blood sample of said human test subject is 3.2 times lower than said level of RNA encoded by said gene in said samples of said control subjects classified as healthy subjects with a p value equal to 0.04.

71. (New) The method of claim 58 or claim 59, wherein said blood sample is selected from the group consisting of: a whole blood sample, a blood sample which has not been fractionated into cell types, and a blood sample which comprises leukocytes which have not been fractionated into cell types.

72. (New) The method of claim 60, wherein said blood sample is selected from the group consisting of: a whole blood sample, a blood sample in which has not been fractionated into cell types, and a blood sample which comprises leukocytes which have not been fractionated into cell types.

73. (New) The method of claim 61, wherein:

- (i) said blood sample of said test subject and said blood samples of said control subjects are whole blood samples; or
- (ii) said blood sample of said test subject and said blood samples of said control subjects are blood samples which have not been fractionated into cell types; or
- (iii) said blood sample of said test subject and said blood samples of said control subjects are blood samples which comprise leukocytes which have not been fractionated into cell types.

74. (New) The method of claim 69 or claim 70, wherein:

- (i) said blood sample of said test subject and said blood samples of said control subjects are whole blood samples; or
- (ii) said blood sample of said test subject and said blood samples of said control subjects are blood samples which have not been fractionated into cell types; or
- (iii) said blood sample of said test subject and said blood samples of said control subjects are blood samples which comprise leukocytes which have not been fractionated into cell types.

75. (New) A method of identifying a *Homo sapiens* tumor necrosis factor receptor superfamily, member 7 (TNFRSF7) gene as a candidate biomarker for bladder cancer in a human subject, said method comprising:

- (a) detecting RNA encoded by said gene in blood samples of human patients diagnosed as having bladder cancer, using an oligonucleotide of predetermined sequence which is specific only for RNA encoded by said gene in said samples, and/or for cDNA complementary to RNA encoded by said gene in said samples; and
- (b) quantifying a level of RNA encoded by said gene in said samples; and
- (c) comparing said level to a quantified level of control RNA encoded by said gene in blood samples of healthy control subjects;

wherein said gene is a candidate biomarker for bladder cancer in a human subject if said level of RNA encoded by said gene in said samples of said human patients diagnosed as having bladder cancer is at least 3 times lower than said level of RNA encoded by said gene in said samples of said healthy subjects with a p value less than 0.05.

76. (New) A method of identifying a *Homo sapiens* tumor necrosis factor receptor superfamily, member 7 (TNFRSF7) gene as a candidate biomarker for bladder cancer in a human subject, said method comprising:

- (a) detecting RNA encoded by said gene in blood samples of human patients diagnosed as having bladder cancer, using an oligonucleotide of predetermined sequence which is specific only for RNA encoded by said gene in said samples, and/or for cDNA complementary to RNA encoded by said gene in said samples; and
- (b) quantifying a level of RNA encoded by said gene in said samples; and

(c) comparing said level to a quantified level of control RNA encoded by said gene in blood samples of healthy control subjects;

wherein said gene is a candidate biomarker for bladder cancer in a human subject if said level of RNA encoded by said gene in said blood samples of said human patients diagnosed as having bladder cancer is 3.2 times lower than said level of RNA encoded by said gene in said samples of said healthy subjects with a p value equal to 0.04.

77. (New) The method of claim 75 or claim 76, wherein:

- (i) said blood samples of said human patients diagnosed as having bladder cancer and said blood samples of said healthy control subjects are whole blood samples; or
- (ii) said blood samples of said human patients diagnosed as having bladder cancer and said blood samples of said healthy control subjects are blood samples which have not been fractionated into cell types; or
- (iii) said blood samples of said human patients diagnosed as having bladder cancer and said blood samples of said control subjects are blood samples which comprise leukocytes which have not been fractionated into cell types.

78. (New) The method of claim 75 or claim 76, wherein said quantifying of said level of RNA encoded by said gene is effected by:

- (i) quantifying said level of RNA relative to a housekeeping gene; or
- (ii) quantification of cDNA complementary to RNA encoded by said gene; or
- (iii) using quantitative PCR; or
- (iv) using an array.

79. (New) A method of classifying *Homo sapiens tumor necrosis factor receptor superfamily, member 7 (TNFRSF7)* gene expression in a human test subject, said method comprising:

- (a) quantifying a level of RNA encoded by said gene in a blood sample of said test subject;
- (b) comparing said level in said sample of said test subject with a quantified level of RNA encoded by said gene in blood samples of control subjects classified as having bladder cancer; and

(c) comparing said level in said sample of said test subject with a quantified level of RNA encoded by said gene in blood samples of control subjects classified as healthy subjects; wherein a determination from steps (b) and (c) that said level in said sample of said test subject is statistically similar to said level in said samples of said subjects classified as having bladder cancer and is statistically lower relative to said level in said samples of said subjects classified as healthy subjects, results in a classification of TNFRSF7 gene expression in said test subject with that of said subjects classified as having bladder cancer, and wherein a determination from steps (b) and (c) that said level in said sample of said test subject is statistically higher relative to said level in said samples of said subjects classified as having bladder cancer and is statistically similar to said level in said samples of said subjects classified as healthy subjects, results in a classification of TNFRSF7 gene expression in said test subject with that of said subjects classified as healthy subjects.